Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||ATLCAR.CD30 cells + Cyclophosphamide + Fludarabine|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|ATLCAR.CD30 cells||CAR.CD30-expressing Autologous T Lymphocytes||ATLCAR.CD30 cells are autologous T-lymphocytes engineered to express a chimeric antigen receptor that targets CD30, potentially leading to immune response against CD30-positive tumor cells (PMID: 30841880).|
|Cyclophosphamide||Cytoxan||CPM||Chemotherapy - Alkylating 16||Cytoxan (cyclophosphamide) is an alkylating agent, which inhibits DNA replication (NCI Drug Dictionary). Cytoxan (cyclophosphamide) is FDA approved in multiple hematological malignancies, breast cancer, neuroblastoma, ovarian cancer, and retinoblastoma (NCI Drug Dictionary).|
|Fludarabine||Fludara||FAMP|Fludarabine phosphate||Flurdara (fludarabine) is converted to 2-fluoro-ara-ATP intracellularly, which potentially inhibits DNA polymerase alpha, ribonucleotide reductase and DNA primase, leading to decreased DNA synthesis and reduced tumor growth (NCI Drug Dictionary)|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT05634785||Phase II||ATLCAR.CD30 cells + Cyclophosphamide + Fludarabine||CD30 CAR for CD30+ NSGCT||Recruiting||USA||0|
|NCT02917083||Phase I||ATLCAR.CD30 cells + Cyclophosphamide + Fludarabine||CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30) (RELY-30)||Recruiting||USA||0|